Table 5.
Base-case analysis result comparing warfarin and DOACs.
| Strategy | Cost ($) | Incremental cost | QALY | ICER ($/QALY) |
|---|---|---|---|---|
| Warfarin | 2,874 | Ref. | 10.83 | Ref. |
| Rivaroxaban | 6,379 | 3,505 | 10.95 | 29,743.99 |
| Apixaban | 5,151 | 2,276 | 11.10 | 8,426.71 |
| Dabigatran | 5,761 | 2,886 | 10.49 | −8,483.04 |
| Edoxaban | 5,851 | 2,976 | 10.99 | 18,483.55 |
ICER, incremental cost-effectiveness ratio; QALY, quality adjusted life year; DOACs, direct oral antagonist oral anticoagulants.